Prix Galien is a annual industry award recognizing excellence in Healthcare. Organized by The Galien Foundation, it covers the Global region. Established in 1970.
The Prix Galien is widely regarded as the life-sciences industry's most prestigious innovation prize. Created in France in 1970 by pharmacist Roland Mehl in homage to Galen of Pergamum, it is coordinated internationally by the Galien Foundation and now operates through national chapters in more than a dozen countries, including the USA, UK, France, Italy, Poland, Sweden, South Korea, India, Japan and an Africa program. In each member nation the Award Committee is composed of up to thirteen leading biomedical scientists — including Nobel laureates in medicine — who typically serve six-year terms. Committees explicitly ignore market size, company scale and development cost, judging only the scientific merit and patient impact of the product itself.
The core categories are Best Pharmaceutical Product, Best Biotechnology Product, Best Medical Technology and Best Digital Health Product; several chapters add awards for rare/orphan-disease products and startups, and the foundation also bestows the Roy Vagelos Pro Bono Humanum Award for humanitarian contributions to global health. There are no gold/silver tiers — a single winner is named per category per country, announced at each nation's annual award ceremony. Because the jury is scientific rather than commercial, a Prix Galien win is treated inside biopharma as a career- and product-defining validation, often compared to the field's highest honors.
Entry is made to the national committee of the country where the product is approved: eligible products must generally be authorized by that nation's health authority and available on the domestic market (in the USA, full FDA approval within roughly the previous five years is required — provisional approvals do not qualify). Application windows last several months and vary by member nation, so check your local chapter's calendar early. The foundation does not publish entry fees. Strong submissions lead with clinical evidence, clearly articulate the unmet medical need addressed, and demonstrate real-world patient impact rather than commercial performance.